‌

US Patent 11306071 Heterocyclic compounds as adenosine antagonists

Patent 11306071 was granted and assigned to Nuvation Bio on April, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

April 19, 2022

Patent Application Number

16746763

Date Filed

January 17, 2020

Patent Citations

US Patent 10328074 Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors

US Patent 10336697 Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors

US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors

US Patent 10363257 Bicyclic bromodomain inhibitors

US Patent 10370356 Pyridinone dicarboxamide for use as bromodomain inhibitors

US Patent 10370374 Heterocyclic compounds and uses thereof

US Patent 10377769 Benzopiperazine compositions as BET bromodomain inhibitors

US Patent 10391175 BET bromodomain inhibitors and therapeutic methods using the same

...

Patent Primary Examiner

Emily A Bernhardt

CPC Code

5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11306071 Heterocyclic compounds as adenosine antagonists

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.